{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:41:31Z","timestamp":1784140891570,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007210","name":"Varian Medical Systems Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.03.033","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T19:03:33Z","timestamp":1743361413000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial"],"prefix":"10.1016","volume":"125","author":[{"given":"Maneesh","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Katdare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchismita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayak","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Phurailatpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahima","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Anaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazneen Husain","family":"Chougle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Sable","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh","family":"Rangarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyamvada","family":"Maitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-9319","authenticated-orcid":false,"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.03.033_bib0001","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning","volume":"53","author":"Cellini","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0002","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0003","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.radonc.2017.12.022","article-title":"Standard whole prostate gland radiotherapy with and without lesion boost in prostate cancer: toxicity in the FLAME randomized controlled trial","volume":"127","author":"Monninkhof","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109713","article-title":"From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial","volume":"185","author":"De Cock","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0006","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1748-717X-8-183","article-title":"3 tesla multiparametric MRI for GTV-definition of dominant intraprostatic lesions in patients with prostate cancer \u2013 an interobserver variability study","volume":"8","author":"Rischke","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0007","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2018.11.031","article-title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","volume":"75","author":"Johnson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0008","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2019.07.005","article-title":"[68Ga-]PSMA-11 PET\/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - implications for focal radiotherapy planning in primary prostate cancer","volume":"141","author":"Bettermann","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0009","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13014-023-02375-5","article-title":"Use of focal radiotherapy boost for prostate cancer: radiation oncologists\u2019 perspectives and perceived barriers to implementation","volume":"18","author":"Zhong","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0010","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","article-title":"Simultaneous 68Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer","volume":"70","author":"Eiber","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0011","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.juro.2016.02.3000","article-title":"Prostate specific membrane antigen positron emission tomography may improve the diagnostic accuracy of multiparametric magnetic resonance imaging in localized prostate cancer","volume":"196","author":"Rhee","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0012","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41391-018-0048-7","article-title":"68Ga-PSMA PET\/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology","volume":"21","author":"Berger","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0013","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.2967\/jnumed.116.189233","article-title":"Intraindividual comparison of 18F-PSMA-1007 PET\/CT, multiparametric MRI, and radical prostatectomy specimens in patients with primary prostate cancer: a retrospective, proof-of-concept study","volume":"58","author":"Kesch","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0014","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.118.221010","article-title":"Combination of 68Ga-PSMA PET\/CT and multiparametric MRI improves the detection of clinically significant prostate cancer: a lesion-by-lesion analysis","volume":"60","author":"Chen","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0015","article-title":"Using 18F-DCFPyL prostate-specific membrane antigen-directed positron emission tomography\/magnetic resonance imaging to define intraprostatic boosts for prostate stereotactic body radiation therapy","volume":"8","author":"Floberg","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-018-1036-8","article-title":"Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET\/CT and MRI: a planning study based on histology reference","volume":"13","author":"Zamboglou","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.7150\/thno.16638","article-title":"Comparison of 68Ga-HBED-CC PSMA-PET\/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology","volume":"7","author":"Zamboglou","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0018","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ijrobp.2022.04.020","article-title":"PSMA-PET- and MRI-based focal dose escalated radiation therapy of primary prostate cancer: planned safety analysis of a nonrandomized 2-armed phase 2 trial (ARO2020-01)","volume":"113","author":"Zamboglou","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0019","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0020","doi-asserted-by":"crossref","first-page":"558","DOI":"10.4097\/kja.19087","article-title":"Multicollinearity and misleading statistical results","volume":"72","author":"Kim","year":"2019","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0021","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/j.ijrobp.2022.07.1185","article-title":"ReIGNITE RT boost: an international study testing the feasibility, accuracy and reliability of using restriction spectrum imaging (RSI) MRI to guide radiotherapy target volume delineation for prostate cancer tumor boost","volume":"114","author":"Lui","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0022","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ijrobp.2024.06.007","article-title":"Clinical impact of contouring variability for prostate cancer tumor boost","volume":"120","author":"Zhong","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0023","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/RLU.0000000000005220","article-title":"Reducing false-positives due to urinary stagnation in the prostatic urethra on 18 F-DCFPyL PSMA PET\/CT with MRI","volume":"49","author":"Gelikman","year":"2024","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0024","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.urolonc.2011.04.002","article-title":"Focal positive prostate-specific membrane antigen (PSMA) expression in ganglionic tissues associated with prostate neurovascular bundle: implications for novel intraoperative PSMA-based fluorescent imaging techniques","volume":"31","author":"Chaux","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00259-018-3954-y","article-title":"68Ga-PSMA-PET\/CT imaging of localized primary prostate cancer patients for intensity modulated radiation therapy treatment planning with integrated boost","volume":"45","author":"Thomas","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0026","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ijrobp.2014.12.052","article-title":"Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET\/CT","volume":"91","author":"Kuang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0027","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1016\/j.ijrobp.2012.01.087","article-title":"Intensity modulated radiation therapy dose painting for localized prostate cancer using 11C-choline positron emission tomography scans","volume":"83","author":"Chang","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0028","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/JU.0000000000002293","volume":"207","author":"Raveenthiran","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0029","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1038\/s41598-021-85028-5","article-title":"The impact of the co-registration technique and analysis methodology in comparison studies between advanced imaging modalities and whole-mount-histology reference in primary prostate cancer","volume":"11","author":"Zamboglou","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0030","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/cancers13225795","article-title":"PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (HypoFocal-SBRT): study protocol of a randomized, multicentric phase III trial","volume":"13","author":"Zamboglou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0031","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.3390\/cancers15194888","article-title":"Focal boost in prostate cancer radiotherapy: a review of planning studies and clinical trials","volume":"15","author":"Zhao","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110070","article-title":"Using multiparametric magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography to detect and delineate the gross tumour volume of intraprostatic lesions \u2013 a systematic review and meta-analysis","volume":"192","author":"Dhar","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600690","article-title":"Comparison of manual and semi-automatic [18F]PSMA-1007 PET based contouring techniques for intraprostatic tumor delineation in patients with primary prostate cancer and validation with histopathology as standard of reference","volume":"10","author":"Spohn","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0034","first-page":"1644","article-title":"The PRIMARY score: using intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis","volume":"63","author":"Emmett","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0035","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/MNM.0000000000001283","article-title":"Pilot study comparing dominant intraprostatic lesion volume using Ga-68 prostate-specific membrane antigen PET-computed tomography and multiparametric MRI","volume":"41","author":"Sasidharan","year":"2020","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0036","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13244-020-00926-y","article-title":"Lesion-to-background ratio threshold value of SUVmax of simultaneous [68Ga]Ga-PSMA-11 PET\/MRI imaging in patients with prostate cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"Insights Imaging"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0037","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.prro.2023.05.004","article-title":"Prostate stereotactic body radiation therapy with a focal simultaneous integrated boost: 5-year toxicity and biochemical recurrence results from a prospective trial","volume":"13","author":"Maas","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0038","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijrobp.2023.05.004","article-title":"Toxicity and patient-reported quality-of-life outcomes after prostate stereotactic body radiation therapy with focal boost to magnetic resonance imaging-identified prostate cancer lesions: results of a phase 2 trial","volume":"117","author":"Morris","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0039","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2024.03.009","article-title":"Simultaneous focal boost with stereotactic radiation therapy for localized intermediate- to high-risk prostate cancer: primary outcomes of the SPARC phase 2 TRIAL","volume":"120","author":"Yasar","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0040","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0041","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0042","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41585-022-00670-6","article-title":"Using PSMA imaging for prognostication in localized and advanced prostate cancer","volume":"20","author":"Roberts","year":"2023","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ijrobp.2025.03.033_bib0043","article-title":"Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography\/multiparametric magnetic resonance imaging","volume":"31","author":"Grefve","year":"2024","journal-title":"Phys Imaging Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625002615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:33:55Z","timestamp":1782030835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625002615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625002615"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.033","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PSMA-PET-Guided Intraprostatic Boost in Prostate SBRT (PROBE): A Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.03.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}